[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336409-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336409-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","disarib-a-specific-bcl2-inhibitor-induces-apoptosis-in-triple-negative-breast-cancer-cells-and-impedes-tumour-progression-altering-mitochondria-associated-processes","Disarib, a Specific BCL2 Inhibitor - Induces Apoptosis in Triple-Negative Breast Cancer Cells and Impedes Tumour Progression - Altering Mitochondria-Associated Processes","","Targeted cancer therapy relies on small-molecule inhibitors to disrupt proteins that drive cancer progression. BCL2 is frequently overexpressed in breast cancer, making it a tractable anti-cancer target. Disarib is a selective BCL2 inhibitor that disrupts BCL2–BAK interaction and activates intrinsic apoptotic signalling while sparing normal cells. The study evaluates Disarib in triple-negative breast cancer cells and xenografts, showing increased apoptosis, reduced tumour growth, and changes in mitochondrial dynamics, energy metabolism, and EMT.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/disarib-a-specific-bcl2-inhibitor-induces-apoptosis-in-triple-negative-breast-cancer-cells-and-impedes-tumour-progression-altering-mitochondria-associated-processes/336409/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/disarib-a-specific-bcl2-inhibitor-induces-apoptosis-in-triple-negative-breast-cancer-cells-and-impedes-tumour-progression-altering-mitochondria-associated-processes/336409.png","ImageObject",300,407,{"name":42,"@type":43},"Maeve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is Disarib and what does it target in cancer cells?","Question",{"text":63,"@type":64},"Disarib is a selective BCL2 inhibitor. It disrupts BCL2–BAK interaction and activates intrinsic apoptotic pathways.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does Disarib affect triple-negative breast cancer (TNBC) cells?",{"text":68,"@type":64},"Disarib increases reactive oxygen species, induces intrinsic apoptosis, and alters colony-forming properties in TNBC cells such as MDA-MB-231 and MDA-MB-468.",{"name":70,"@type":61,"acceptedAnswer":71},"What in vivo and molecular effects were observed after Disarib treatment?",{"text":72,"@type":64},"In xenografts, Disarib significantly reduces tumour growth. Transcriptomics and gene expression analyses indicate effects on Oxphos and glycolytic genes, mitochondrial fission, wound healing, and inhibition of EMT.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336409,1790474926,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Article  \nDisarib, a Specific BCL2 Inhibitor, Induces Apoptosis in Triple-Negative Breast Cancer Cells and Impedes Tumour Progression in Xenografts by Altering Mitochondria-Associated Processes  \nMeghana Manjunath 1, Febina Ravindran 1, Shivangi Sharma 1,2, Humaira Siddiqua 2, Sathees C. Raghavan 2 and Bibha Choudhary 1, *  \nCitation: Manjunath, M.; Ravindran, F.; Sharma, S.; Siddiqua, H.;  \nRaghavan, S.C.; Choudhary, B. Disarib, a Specific BCL2 Inhibitor, Induces Apoptosis in Triple-Negative Breast Cancer Cells and Impedes Tumour Progression in Xenografts by Altering Mitochondria-Associated Processes. Int. J. Mol. Sci. 2024, 25, 6485. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25126485  \nAcademic Editors: Silvio Naviglio and Luigi Sapio  \nReceived: 3 April 2024  \nRevised: 23 May 2024  \nAccepted: 24 May 2024  \nPublished: 12 June 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Biotechnology and Applied Bioinformatics, Institute of Bioinformatics and Applied Biotechnology, Electronic City Phase 1, Bengaluru 560100, India  \n2 Indian Institute of Science, Bengaluru 560012, India; [humairas@iisc.ac.in](humairas@iisc.ac.in) (H.S.); [sathees@iisc.ac.in](sathees@iisc.ac.in) (S.C.R.)  \n* [Correspondence: vibha@ibab.ac.in](Correspondence: vibha@ibab.ac.in); Tel.: +91-80-285289-00 (ext. 105)  \nAbstract: Targeted cancer therapy aims to disrupt the functions of proteins that regulate cancer progression, mainly by using small molecule inhibitors (SMIs) . SMIs exert their effect by modulating signalling pathways, organelle integrity, chromatin components, and several biosynthetic processes essential for cell division and survival. Antiapoptotic protein BCL2 is highly upregulated in many cancers compared with normal cells, making it an ideal target for cancer therapy. Around 75% of primary breast cancers overexpress BCL2, providing an opportunity to explore BCL2 inhibitors as a therapeutic option. Disarib is an SMI that has been developed as a selective BCL2 inhibitor. Disarib works by disrupting BCL2-BAK interaction and activating intrinsic apoptotic pathways in leukemic cells while sparing normal cells. We investigated the effects of Disarib, a BCL2 specific inhibitor, on breast cancer cells and xenografts. Cytotoxicity and fluorometric assays revealed that Disarib induced cell death by increasing reactive oxygen species and activating intrinsic apoptotic pathways in Triple-Negative Breast Cancer cells (MDA-MB-231 and MDA-MB-468) . Disarib also affected the colony-forming properties of these cells. MDA-MB-231-and MDA-MB-468-derived xenografts showed a significant reduction in tumours upon Disarib treatment. Through the transcriptomics approach, we also explored the influence of BCL2 inhibitors on energy metabolism, mitochondrial dynamics, and epithelial-to-mesenchymal transition (EMT) . Mitochondrial dynamicsand glucose metabolism mainly regulate energy metabolism. The change in energetics regulates tumour growth through epithelial–mesenchymal transition, and angiogenesis. RNA sequencing (RNAseq) analysis revealed that BCL2 inhibitors ABT-199 and Disarib maintain Oxphos levels in MDA-MB-231 . However, key glycolytic genes were significantly downregulated. Mitochondrial fission genes were seen to be downregulated both in RNAseq data and semi quantitative real time polymerase chain reaction (qRTPCR) in Disarib-treated TNBC cells and xenografts. Lastly, Disarib inhibited wound healing and epithelial-to-mesenchymal transition. This study showed that Disarib disrupts mitochondrial function, activates the intrinsic apoptotic pathway in breast cancer, and inhibits epithelial-to","cbCainIdmHMVT8cR","https://ap.wps.com/l/cbCainIdmHMVT8cR","pdf",9633654,25,"English","# Abstract\n# Keywords\n# 1. Introduction\n## Metastasis and EMT in TNBC\n## Metabolic reprogramming and the Warburg effect","[{\"question\":\"What is Disarib and what does it target in cancer cells?\",\"answer\":\"Disarib is a selective BCL2 inhibitor. It disrupts BCL2–BAK interaction and activates intrinsic apoptotic pathways.\"},{\"question\":\"How does Disarib affect triple-negative breast cancer (TNBC) cells?\",\"answer\":\"Disarib increases reactive oxygen species, induces intrinsic apoptosis, and alters colony-forming properties in TNBC cells such as MDA-MB-231 and MDA-MB-468.\"},{\"question\":\"What in vivo and molecular effects were observed after Disarib treatment?\",\"answer\":\"In xenografts, Disarib significantly reduces tumour growth. Transcriptomics and gene expression analyses indicate effects on Oxphos and glycolytic genes, mitochondrial fission, wound healing, and inhibition of EMT.\"}]","Disarib, a Specific BCL2 Inhibitor - Induces Apoptosis in Triple-Negative Breast Cancer Cells and Impedes Tumour Progression - Altering Mitochondria-Associated Processes | PDF",1790014938,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01dc4b43d63817fc190082d5728053ac.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfe07a363667a470af848682ef3b7dae.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/014f38984361070f3a6a8138b7bbd96c.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d5d85e2a9345a92b3b94f355cc2f57d.webp",980,1385]